EUVIMEDEUVIMED entdecken
Crossref

uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target

William T Maich iD, Muhammad Vaseem Shaikh, Anish Puri, Martin A Rossotti iD, Shan Grewal, Aapti Khanna iD, Alisha Anand, Nicholas Mikolajewicz iD, Mathieu P Seyfrid iD, Dillon A McKenna, Minomi Subapanditha, Daniel Mobilio iD und 18 weitere

Science Translational Medicine · 2026

DOI: 10.1126/scitranslmed.aea8381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von William T Maich und 29 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada. Hauptthemen laut MEDLINE: Glioblastoma, Receptors, Urokinase Plasminogen Activator, T-Lymphocytes, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 124 Literaturangaben. Gefördert von: McMaster University, Terry Fox Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) comprises nearly 15% of primary central nervous system (CNS) tumors and 50% of malignant primary CNS tumors worldwide. Considerable tumoral heterogeneity exists in GBM, leading to inefficacy of current treatments and the absence of meaningful improvements in frontline therapies in the past 20 years. Through multiomic analysis of patient-derived primary and recurrent GBM cell lines, we identified the urokinase plasminogen activator receptor (uPAR) as a protumorigenic marker of putative brain tumor–initiating cells and a potential therapeutic target. We found that genetic disruption of uPAR expression impaired protumorigenic characteristics in vitro and in vivo, highlighting its biological role in tumorigenesis. We then generated uPAR-specific chimeric antigen receptor (CAR) T cells, which demonstrated potent antitumor activity in recurrent GBM patient–derived xenograft models. In addition to direct tumor cell killing, we found that uPAR is expressed on GBM-associated macrophages, enabling uPAR CAR T cells to target both GBM itself and cells in the tumor microenvironment. Together, these data illustrate the potency and therapeutic potential of targeting uPAR in GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaReceptors, Urokinase Plasminogen ActivatorT-LymphocytesReceptors, Chimeric AntigenBrain NeoplasmsImmunotherapy, AdoptiveNeoplasm Recurrence, LocalHumansAnimalsCell Line, TumorXenograft Model Antitumor AssaysTumor MicroenvironmentMacrophages

Substanzen

Receptors, Urokinase Plasminogen ActivatorReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.
  • Department of Surgery, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada.
  • Human Health Therapeutics Research Centre, Life Sciences Division, National Research Council Canada, Ottawa, ON, Canada.
  • Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.
  • Program for Genetics and Genome Biology, Hospital for Sick Children, Peter Gilgan Centre for Research & Learning, Toronto, ON, Canada.
  • Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

ORCID-Profile: William T Maich, Martin A Rossotti, Aapti Khanna, Nicholas Mikolajewicz, Mathieu P Seyfrid, Daniel Mobilio, Greg Hussack, Joey G Sheff, Jennifer J Hill, Mo Taleb, Abdelsimar Omar, Chirayu Chokshi, Kui Zhai, Shawn C Chafe, Jason Moffat, Thomas Kislinger, Sheila K Singh

Förderung

  • McMaster University
  • Terry Fox Research Institute

Zitieren

APA

Maich, W. T., Shaikh, M. V., Puri, A., Rossotti, M. A., Grewal, S., Khanna, A., Anand, A., Mikolajewicz, N., Seyfrid, M. P., McKenna, D. A., Subapanditha, M., Mobilio, D., Hussack, G., Sheff, J. G., Hill, J. J., Taleb, M., Kwiecien, J. M., Salim, S., Savage, N., …, & Singh, S. K. (2026). uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aea8381

Vancouver

Maich WT, Shaikh MV, Puri A, Rossotti MA, Grewal S, Khanna A, et al. uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aea8381

BibTeX
@article{Maich2026,
  author = {Maich, William T and Shaikh, Muhammad Vaseem and Puri, Anish and Rossotti, Martin A and Grewal, Shan and Khanna, Aapti and Anand, Alisha and Mikolajewicz, Nicholas and Seyfrid, Mathieu P and McKenna, Dillon A and Subapanditha, Minomi and Mobilio, Daniel and Hussack, Greg and Sheff, Joey G and Hill, Jennifer J and Taleb, Mo and Kwiecien, Jacek M and Salim, Sabra and Savage, Neil and Wang, Bill and Sharma, Sunjay and Omar, Abdelsimar and Chokshi, Chirayu and Zhai, Kui and Chafe, Shawn C and Moffat, Jason and Kislinger, Thomas and Venugopal, Chitra and Henry, Kevin A and Singh, Sheila K},
  title = {uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target},
  journal = {Science Translational Medicine},
  year = {2026},
  doi = {10.1126/scitranslmed.aea8381}
}
Kostenlos starten →